ceftolozane / tazobactam

This medicine is authorised for use in the European Union.


Zerbaxa is an antibiotic used to treat adults and children with:

• complicated (difficult to treat) infections of tissues and organs within the belly (intra-abdominal infections);

• serious kidney infection (acute pyelonephritis);

• complicated infections of the urinary tract (structures that carry urine, such as the bladder).

It is also used to treat adults with hospital-acquired pneumonia (an infection of the lungs that is caught in the hospital), including ventilator-associated pneumonia (pneumonia in patients using a ventilator, a machine that helps a patient to breathe).

Zerbaxa contains the active substances ceftolozane and tazobactam.

This EPAR was last updated on 14/04/2023

Authorisation details

Product details
Agency product number
Active substance
  • ceftolozane sulfate
  • tazobactam sodium
International non-proprietary name (INN) or common name
  • ceftolozane
  • tazobactam
Therapeutic area (MeSH)
Bacterial Infections
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Merck Sharp & Dohme B.V. 
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Waarderweg 39
2031 BN Haarlem
The Netherlands

Product information

25/07/2022 Zerbaxa - EMEA/H/C/003772 - II/0036

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antibacterials for systemic use

Therapeutic indication

Zerbaxa is indicated for the treatment of the following infections in adults:

  • Complicated intra abdominal infections;
  • Acute pyelonephritis;
  • Complicated urinary tract infections;
  • Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Assessment history

Related content

How useful was this page?

Add your rating
1 rating